On Thursday shares of Calithera Biosciences, Inc. (NASDAQ:CALA) closed at $12.14. Company’s EPS growth for next 5 years is recorded as 75.00%.Calithera Biosciences, Inc. (NASDAQ:CALA) announced its participated at the Bank of America Merrill Lynch 2015 Healthcare Conference, on Tuesday, May 12, 2015 at 8:00 a.m. Pacific Time at The Encore at Wynn Hotel in Las Vegas, NV.
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) in last trading activity decreased -0.94% to close at $2.10. Company weekly performance is -0.47% while its quarterly performance stands at 11.70%. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) is -50.00% away from its 52 week high. Protalix BioTherapeutics, Inc. (NYSE:PLX) announced that Moshe Manor, the Company’s President and Chief Executive Officer, will present a corporate overview at the 2015 UBS Global Healthcare Conference on Wednesday, May 20, 2015 at 10:30 AM ET, at The Sheraton New York Times Square Hotel, New York, NY.
On last trading day KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) decreased -1.82% to close at $0.48. Its volatility for the week is 6.51% while volatility for the month is 8.29%. KBIO’s EPS growth for past 5 years was 42.90%. KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) monthly performance is -9.23%. On May 11, KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) reported its financial results for the first quarter of 2015. Net loss for the quarter ended March 31, 2015 was $9.6 million or $0.29 per common share, as compared to $10.4 million or $0.32 per common share for the same period in 2014.
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) has 1.40% insider ownership while its institutional ownership stands at 76.10%. In last trading activity company’s stock closed at $10.22. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that Greg Madison, the Company’s Chief Executive Officer, presented a company overview, including progress with the commercialization of Auryxia™ (ferric citrate) in the United States, at the Bank of America Merrill Lynch 2015 Health Care Conference, held at the Encore at the Wynn in Las Vegas, NV on May 12-14, 2015.
On last trading day TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) decreased -4.35% to close at $2.42. Its volatility for the week is 13.17% while volatility for the month is 17.68%. TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) monthly performance is -43.72%. Stock analysts at Needham & Company LLC lowered their price target on shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) from $10.00 to $7.00 in a report issued on Thursday. The firm currently has a “buy” rating on the stock.